Can someone give a review of exclusions we have in our s/c trial? Are patients on ventilation allowed into our trial, seems they would be the hardest to save, and would thus diminish our results? Interesting clever move for HGEN, increasing their odds of meeting the endpoint? But Humanigen is still blinded?